News & Events
July 20, 2021
Digital Health Technologies Hold Key to New Parkinson’s TreatmentsGlobal stakeholders come together to collaborate with urgency to address unmet needs for Parkinson’s therapies. TUCSON, Ariz., July 20, 2021 — The use of digital health technologies across health care and drug development has accelerated. A new paper titled “Digital Progression Biomarkers as Novel Endpoints in Clinical Trials: A Multistakeholder Perspective,” co-authored by experts across......
July 15, 2021
Launch of UNITE4TB Partnership Marks a New Era in Tuberculosis Treatment Development
To advance anti-tuberculosis (TB) science and enable the progression of new, safe, and affordable treatment solutions for TB patients worldwide, a new consortium of 30 partners from 13 countries has officially launched. The 7-year, €185 million project called UNITE4TB, aims to accelerate and improve the clinical evaluation of combinations of existing and novel drugs, with the goal of developing new and highly active TB treatment regimens for drug-resistant and -sensitive TB.
July 8, 2021
C-Path Announces Health Care Leader Appointment to Board of Directors
TUCSON, Ariz., July 8, 2021 — Critical Path Institute today announced the appointment of health care industry leader and active civic involvement pioneer Mara G. Aspinall, MBA, to its Board of Directors.
June 24, 2021
Clinical Technology Expert and Experienced Neuroscientist Join C-Path in Executive Director Roles
Scottie Kern and Dr. Terina N. Martínez Will Both Serve in Dual Positions
TUCSON, Ariz., June 24, 2021 — Critical Path Institute (C-Path) today announced it has named Scottie Kern, as both Executive Director of the Electronic Patient-Reported Outcome (ePRO) Consortium and Associate Director of the Patient-Reported Outcome (PRO) Consortium and Terina N. Martínez, Ph.D., as Executive Director of both the Duchenne Regulatory Science Consortium (D-RSC) and Critical Path to Therapeutics for the Ataxias (CPTA).
May 25, 2021
C-Path Virtual Workshop to Feature Latest Advances in Clinical Trials for T1D
More than 300 Attendees and 20 Speakers Are Expected to Participate in the International Workshop, June 15-16
TUCSON, Ariz., May 25, 2021 — Critical Path Institute (C-Path) today announced its schedule for the Design of Clinical Trials in New-Onset Type 1 Diabetes: Regulatory Considerations for Drug Development Workshop, to be held virtually June 15-16. Together with the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and in collaboration with Benaroya Research Institute, INNODIA and JDRF, this 2-day public workshop will focus on the implementation of endpoints and outcome measures for clinical trials in new onset type 1 diabetes (T1D). More than 300 researchers, pharmaceutical representatives, academia members, investigators, T1D patients and regulatory experts from throughout the United States and Europe are expected to gather virtually to hear 15 presentations about T1D research and medical product development.